Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
celgene
6
×
detroit blog main
detroit top stories
fda
6
×
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
clinical trials
eli lilly
gene therapy
johnson & johnson
abbvie
bristol-myers squibb
gene editing
genentech
glaxosmithkline
ipo
merck
What
bio
roundup
6
×
biopharma
companies
crispr
fda
ipo
known
new
news
allogene
approved
arena’s
august
biotech
bounty
busy
cancer
car
celgene
cig
colleagues
comeback
congress
congressional
corner
days
deals
decisions
delivered
devices
digital
disease
diversity
drug
drugs
epidemic
executives
exome
expressing
Language
unset
Current search:
celgene
×
fda
×
roundup
×
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More